KR102061716B1 - Composition for promoting hair growth or restoration containing 21-o-angeloyltheasapogenol e3 - Google Patents
Composition for promoting hair growth or restoration containing 21-o-angeloyltheasapogenol e3 Download PDFInfo
- Publication number
- KR102061716B1 KR102061716B1 KR1020130104230A KR20130104230A KR102061716B1 KR 102061716 B1 KR102061716 B1 KR 102061716B1 KR 1020130104230 A KR1020130104230 A KR 1020130104230A KR 20130104230 A KR20130104230 A KR 20130104230A KR 102061716 B1 KR102061716 B1 KR 102061716B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- hair growth
- angeloylthiasapogenol
- hair
- promoting
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 109
- 230000003779 hair growth Effects 0.000 title claims abstract description 65
- 230000001737 promoting effect Effects 0.000 title claims abstract description 34
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 244000269722 Thea sinensis Species 0.000 claims description 30
- 235000009569 green tea Nutrition 0.000 claims description 30
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 27
- 229930182490 saponin Natural products 0.000 claims description 27
- 150000007949 saponins Chemical class 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 7
- 108090001007 Interleukin-8 Proteins 0.000 claims description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 6
- 229960002986 dinoprostone Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 230000003698 anagen phase Effects 0.000 abstract description 11
- 230000002500 effect on skin Effects 0.000 abstract description 11
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 230000016507 interphase Effects 0.000 abstract description 2
- 230000007704 transition Effects 0.000 abstract description 2
- 238000004904 shortening Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 238000009472 formulation Methods 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 210000004209 hair Anatomy 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 15
- 201000004384 Alopecia Diseases 0.000 description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 14
- -1 foundation Substances 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 239000006210 lotion Substances 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- 208000024963 hair loss Diseases 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 206010068168 androgenetic alopecia Diseases 0.000 description 3
- 201000002996 androgenic alopecia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000013538 functional additive Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 2
- 241001467578 Microbacterium Species 0.000 description 2
- 241000235575 Mortierella Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000031774 hair cycle Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- TXJTZIIDMZBTEB-UHFFFAOYSA-N (3alpha,11alpha)-3,11,23-Trihydroxy-20(29)-lupen-28-oic acid Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CC(O)C3C21C TXJTZIIDMZBTEB-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 241000235402 Rhizomucor Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 229930185199 Sapogenol Natural products 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 241000228341 Talaromyces Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229930192129 Theasapogenol Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 108010084650 alpha-N-arabinofuranosidase Proteins 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010030923 hesperidinase Proteins 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 108010001078 naringinase Proteins 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- OWGHQYPQNSZTFQ-UHFFFAOYSA-M triethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](CC)(CC)CC OWGHQYPQNSZTFQ-UHFFFAOYSA-M 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
일측면에서 본 발명은 21-O-안젤로일티아사포제놀 E3을 유효성분으로 함유하는 발모 또는 육모 촉진용 조성물에 관한 것이다. 다른 일측면에서 본 발명은 모유두 세포증식 및 인체 모낭기관에서의 모발 성장을 촉진시켜 성장주기 중 휴지기에서 성장기로 이행되는 주기를 단축시켜주는 것을 특징으로 하는 21-O-안젤로일티아사포제놀 E3을 포함하는 조성물에 관한 것이다.In one aspect, the present invention relates to a composition for promoting hair growth or hair growth comprising 21-O-angeloylthiasapogenol E3 as an active ingredient. In another aspect, the present invention provides 21-O-angeloylthiasapogenol E3, which promotes dermal papilla cell proliferation and hair growth in human hair follicle organs, thereby shortening the transition period from the resting phase to the growth phase. It relates to a composition comprising.
Description
본 발명은 일측면에서 발모 또는 육모 촉진용 조성물에 관한 것이며, 다른 일측면에서 21-O-안젤로일티아사포제놀(21-O-angeloyltheasapogenol) E3을 포함하여, 모발의 주기 중 휴지기에서 성장기로 이행되는 주기를 단축시켜 모발성장을 촉진시키는 발모 또는 육모 촉진용 조성물에 관한 것이다.The present invention relates to a composition for promoting hair growth or hair growth in one aspect, and 21-O-angeloyltheasapogenol E3 in another aspect, the transition from the resting phase to the growth phase of the hair cycle It relates to a composition for promoting hair growth or hair growth to shorten the cycle to promote hair growth.
탈모의 원인으로는 남성호르몬 작용 과잉설, 피지분비 과잉설, 혈액순환 불량설, 과산화물, 세균 등에 의한 두피기능 저하설, 유전적 요인, 노화, 스트레스 등이 논의되고 있다. 아울러, 사회적 스트레스의 증가와 더불어 환경오염 및 인스턴트 식품 등 서구화된 식습관, 잦은 파마와 염색 등으로 인하여 탈모 인구가 점차 증가하고 있다. 모발의 주기는 모발을 성장시키는 성장기(anagen), 성장을 종료하고 모구부가 축소하는 시기인 퇴화기(catagen), 모유두가 활동을 멈추고 모발을 두피에 머무르게 하는 시기인 휴지기(talogen), 모유두가 활동을 시작하거나 또는 새로운 모발을 발생시켜 오래된 모발을 탈모시키는 시기인 발생기로 나눌 수 있다. The causes of hair loss are discussed, such as hyperthermia of male hormone action, excessive sebum secretion, poor blood circulation, hypoxia caused by peroxide, bacteria, genetic factors, aging, stress. In addition, hair loss population is gradually increasing due to the increase of social stress, westernized eating habits such as environmental pollution and instant food, frequent perm and dyeing, and the like. Hair cycles include anagen, which grows hair, catagen, which ends growth and hairball shrinks, talogen, which is the time when the nipple stops working and the hair stays in the scalp. It can be divided into a generator, which is a time to start or to dehair old hair by generating new hair.
성장기(Anagen Stage; 2~7년)는 모발이 성장하는 기간으로, 다시 모발이 모구로부터 모포로 나가려는 모발 생성 단계와 딱딱한 케라틴이 모낭 안에서 만들어지는 단계로 나누어진다. 모발은 퇴행기까지 자가성장을 계속한다. 퇴행기(Catagen Stage; 2~3주)는 성장기가 끝나고, 모발의 형태를 유지하면서 대사과정이 느려지는 시기로, 이 단계에서는 케라틴을 만들어내지 않는다. 퇴화기는 전체 모발의 1%를 차지한다. 이때 모구부가 수축하여 모유두로 나눠지며 모낭에 둘러싸여 위쪽으로 올라가고, 세포분열은 정지상태이다. 휴지기(Talogen Stage; 3개월)는 모유두가 위축되고 모낭이 차츰 쪼그라들며, 모근이 위쪽으로 밀려 올라가 빠진다. 모발이 없어지는 시기로서 다음 성장기 단계가 시작될 때까지의 수명은 3~4개월이다. The anagen stage (2-7 years) is the period of hair growth, which is divided into the stages of hair production, from which hair exits the hair follicles and the formation of hard keratin in the hair follicles. Hair continues to grow self-development. Cataract Stage (two to three weeks) is the period when the growth phase ends and metabolism slows down while maintaining the shape of the hair. This stage does not produce keratin. The degenerative stage accounts for 1% of all hair. At this time, the hair follicle contracts and is divided into the dermal papilla and surrounded by the hair follicle and rises upward, and the cell division is at a standstill. The Talogen Stage (3 months) is followed by atrophy of the nipples, the hair follicles clumping gradually, and the roots being pushed upwards. The period of hair loss is 3-4 months until the next growth stage begins.
정상인 사람은 성장기 상태의 모발이 많은데 비해 탈모증(Alopecia)인 사람은 휴지기 상태의 모발이 많아 눈으로 보이는 탈모현상이 나타나게 된다. 탈모가 진행될수록 성장기의 기간이 짧아지고 이로 인해 모발은 점점 소형화된다. 따라서, 탈모의 치료를 위해서는 휴지기 상태의 모낭을 성장기로 빨리 갈 수 있도록 하고, 짧아진 성장기를 늘려주는 것이 중요하다.Normal people have a lot of hair growth phase, whereas alopecia (alopecia) people have a lot of hair at rest phase is a visible hair loss phenomenon. As hair loss progresses, the growth phase is shorter, which leads to smaller and smaller hairs. Therefore, for the treatment of hair loss, it is important to allow the hair follicles in the resting state to go to the growth phase quickly and to increase the shortened growth phase.
남성형 탈모증은 테스토스테론(Testosterone)이라는 남성호르몬에 의해 나타나는 현상으로 이 테스토스테론이 5 알파-리덕타아제(α-reductase)라는 효소에 의해 더 강력한 호르몬인 디히드로테스토스테론 (Dihydrotestosterone, DHT)으로 바뀌게 되면, 이 호르몬이 모낭에 작용하여 모낭을 성장기 단계에서 퇴화기 단계로 유도하여 탈모가 일어나게 한다. 따라서, 남성형 탈모증을 치료하기 위하여 5 알파-리덕타아제에 의한 DHT의 생성을 억제하는 방법이 주로 사용된다.Androgenetic alopecia is caused by a male hormone called Testosterone, which is converted into a more powerful hormone, Dihydrotestosterone (DHT), by an enzyme called 5 alpha-reductase. Hormones act on the hair follicles, leading the hair follicles from the growth phase to the degenerative phase, leading to hair loss. Therefore, a method of inhibiting the production of DHT by 5 alpha-reductase is mainly used to treat androgenetic alopecia.
여성형 탈모증은 주로 폐경기 이후 에스트로겐 양의 감소에 의해 발생한다. 여성형 탈모증을 위한 치료제로는 주로 미녹시딜이나 에스트로겐이 사용되고 있다.Gynecologic alopecia is mainly caused by a decrease in the amount of estrogen after menopause. Minoxidil and estrogen are mainly used as treatments for gynecomastia.
원형 탈모증은 자가면역질환이나 정신적 스트레스, 유전적 소인에 의해 발생한다. 이러한 원형 탈모증은 안드로겐성 탈모증과는 근본적으로 원인이 다르며, 치료법 또한 달라서 부신피질 호르몬제를 처리하는 방법을 사용하거나, 미녹시딜을 환부에 바르거나 인위적으로 환부에 자극을 유발하는 방법을 사용한다. Alopecia areata is caused by autoimmune diseases, mental stress, or genetic predisposition. This alopecia areata is fundamentally different from androgenetic alopecia, and the treatment is also different, using a method of treating corticosteroids, or applying minoxidil to the affected area or artificially causing irritation in the affected area.
그러나, 지금까지 탈모를 방지하여 주고 발모촉진 및 모발의 생장에 효과를 가지고 있다고 알려져 있는 미녹시딜(minoxidil) 이나 트리코사카라이드 (trichosaccharide) 등의 제제들의 경우, 뚜렷한 효능의 부재 및 인체 안정성, 피부자극 유발 등의 부작용 문제가 대두되고 있어 안전성 및 효능이 확보된 조성물 개발이 시급한 실정이다. However, in the case of preparations such as minoxidil or trichosaccharide, which are known to prevent hair loss and have an effect on promoting hair growth and hair growth, the absence of obvious efficacy, human stability, and skin irritation are induced. Side effects such as these are emerging, it is urgent to develop a composition that ensures safety and efficacy.
상기와 같은 문제점을 해결하기 위하여 본 발명은 일측면에서 21-O-안젤로일티아사포제놀 E3가 기존에 알려지지 않은 발모 또는 육모 촉진 효능이 있음을 발견하고, 이를 이용한 화장료 조성물, 약학 조성물 및 건강식품 조성물을 제공하는 것을 그 목적으로 한다. In order to solve the above problems, the present invention finds that 21-O-angeloylthiasapogenol E3 has a previously known hair growth or hair growth promoting effect, and a cosmetic composition, a pharmaceutical composition, and a health food using the same. It is an object to provide a composition.
본 발명은 일측면에서, 하기 화학식 1로 표현되는 티아사포제놀(theasapogenol) 유도체를 유효성분으로 함유하는 발모 또는 육모 촉진용 조성물을 제공한다. The present invention provides a composition for promoting hair growth or hair growth which contains, in one aspect, a thiazapogenol derivative represented by the following Chemical Formula 1 as an active ingredient.
[화학식 1][Formula 1]
상기 식에서, R1 및 R2는 각각 독립적으로 -H, C1 -6 알킬, -OH, -R6OH 또는 -CHO이며, Wherein R, R 1 and R 2 are each independently -H, C 1 -6 alkyl, -OH, -R 6 OH or -CHO,
R3는 -H, C1 -6 알킬, -OH, 또는 -OOCR7이고,R 3 is -H, C 1 -6 alkyl, -OH, or -OOCR 7,
R4는 -H 또는 -COR8이며,R 4 is -H or -COR 8 ,
R5는 -H 또는 C1 -6 알킬이고, R 5 is -H or C 1 -6 alkyl,
여기서, R6는 C1 -6 알킬, R7은 C2 -6 알켄일, 및 R8은 C1 -6 알킬이다.Wherein, R 6 is C 1 -6 alkyl, R 7 is C 2 -6 alkenyl, and R 8 is a C 1 -6 alkyl.
본 발명은 다른 일측면에서, 21-O-안젤로일티아사포제놀(21-O-angeloyltheasapogenol) E3를 유효성분으로 포함하는 발모 또는 육모 촉진용 조성물을 제공한다. In another aspect, the present invention provides a composition for promoting hair growth or hair growth comprising 21-O-angeloyltheasapogenol E3 as an active ingredient.
본 발명은 또 다른 일측면에서, 녹차 사포닌으로부터 유래된 티아사포제놀 유도체를 유효성분으로 하며, 일측면에서 유효성분을 조성물 총 중량을 기준으로 0.001 내지 20중량% 함유하는 발모 또는 육모 촉진용 조성물을 제공한다. In another aspect, the present invention provides a thiasapogenol derivative derived from green tea saponin as an active ingredient, and in one aspect, a composition for promoting hair growth or hair growth containing 0.001 to 20% by weight based on the total weight of the composition. to provide.
본 발명은 또 다른 일측면에서, 화장료 조성물, 약학 조성물 또는 식품 조성물인, 발모 또는 육모 촉진용 조성물을 제공한다. In another aspect, the present invention provides a composition for promoting hair growth or hair growth, which is a cosmetic composition, a pharmaceutical composition or a food composition.
일측면에서 본 발명의 조성물은 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3을 함유함으로써, 종래의 발모제보다 더 우수한 발모 또는 육모 촉진 효과를 나타낼 수 있다. In one aspect, the composition of the present invention contains 21-O-angeloylthiasapogenol E3 derived from green tea saponin, thereby exhibiting a better hair growth or hair growth promoting effect than conventional hair regrowth agents.
또한, 식물성 천연물질을 사용하기 때문에 안전성이 우수하므로 발모 또는 육모 촉진을 위한 피부 외용제로 사용할 수 있으며, 화장료 조성물, 약학 조성물 또는 식품 조성물 등에 널리 사용될 수 있다. In addition, because it uses a natural plant material, it is excellent in safety and can be used as an external preparation for promoting hair growth or hair growth, and can be widely used in cosmetic compositions, pharmaceutical compositions or food compositions.
다른 일측면에서 21-O-안젤로일티아사포제놀 E3을 유효성분으로 함유한 조성물은 모낭 모유두 세포를 증식시키는 효과를 가지며, PGE2, IL-6 및 IL-8 생성을 억제하는 효과를 나타낼 수 있다. In another aspect, the composition containing 21-O-angeloylthiasapogenol E3 as an active ingredient has the effect of proliferating follicular dermal papilla cells and may inhibit the production of PGE2, IL-6 and IL-8. .
이하에서는, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
일측면에서 본 발명의 조성물은 하기 화학식 1로 표현되는 티아사포제놀(theasapogenol) 유도체를 유효성분으로 함유하는 발모 또는 육모 촉진용 조성물이다. In one aspect, the composition of the present invention is a composition for promoting hair growth or hair growth containing a thiasapogenol derivative (theasapogenol) derivative represented by the following Chemical Formula 1 as an active ingredient.
[화학식 1][Formula 1]
상기 식에서, R1 및 R2는 각각 독립적으로 -H, C1 -6 알킬, -OH, -R6OH 또는 -CHO이며, Wherein R, R 1 and R 2 are each independently -H, C 1 -6 alkyl, -OH, -R 6 OH or -CHO,
R3는 -H, C1 -6 알킬, -OH, 또는 -OOCR7이고,R 3 is -H, C 1 -6 alkyl, -OH, or -OOCR 7,
R4는 -H 또는 -COR8이며,R 4 is -H or -COR 8 ,
R5는 -H 또는 C1 -6 알킬이고, R 5 is -H or C 1 -6 alkyl,
여기서, R6는 C1 -6 알킬, R7은 C2 -6 알켄일, 및 R8은 C1 -6 알킬이다.Wherein, R 6 is C 1 -6 alkyl, R 7 is C 2 -6 alkenyl, and R 8 is a C 1 -6 alkyl.
다른 일측면에서 본 발명의 조성물은 21-O-안젤로일티아사포제놀 E3을 포함하는 발모 또는 육모 촉진용 조성물이다.In another aspect, the composition of the present invention is a composition for promoting hair growth or hair growth comprising 21-O-angeloylthiasapogenol E3.
또 다른 일측면에서 상기의 21-O-안젤로일티아사포제놀 E3은 하기 화학식 2로 표현되는 것일 수 있다. 즉, 하기 화학식 2는 상기 화학식 1에서 R1은 -CHO, R2는 -CH3, R3는 -OCOC(CH3)=CHCH3, R4는 -COCH3 및 R5는 -CH3인 티아사포제놀 유도체에 해당된다. In another aspect, the 21-O-angeloylthiasapogenol E3 may be represented by the following Chemical Formula 2. That is, in Formula 2, in Formula 1, R 1 is -CHO, R 2 is -CH 3 , R 3 is -OCOC (CH 3 ) = CHCH 3 , R 4 is -COCH 3 and R 5 is -CH 3 . Corresponds to thiasapogenol derivatives.
[화학식 2][Formula 2]
또 다른 일측면에서 상기의 화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3은 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3일 수 있다. 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3은 녹차 종자로부터 물 또는 유기용매를 이용하여 사포닌을 함유하는 추출물을 수득하는 단계; 및 상기 추출물을 산, 염기, 효소 또는 상기 효소를 생산하는 미생물을 이용하여 가수분해함으로써 21-O-안젤로일티아사포제놀 E3을 분리하는 단계를 포함하는 제조방법을 통해서 제조될 수 있다. In another aspect, the thiazapogenol derivative or 21-O-angeloylthiasapogenol E3 represented by Chemical Formula 1 may be 21-O-angeloylthiasapogenol E3 derived from green tea saponin. 21-O-angeloylthiasapogenol E3 derived from green tea saponin is obtained by extracting saponin from water of green tea seeds using water or an organic solvent; And separating 21-O-angeloylthiasapogenol E3 by hydrolyzing the extract using an acid, a base, an enzyme, or a microorganism producing the enzyme.
상기 유기용매는 에탄올, 메탄올, 부탄올, 에테르, 에틸아세테이트 및 클로로포름을 포함하는 군으로부터 선택된 하나 이상의 유기용매 또는 이들과 물의 혼합물, 일측면에서 50% 에탄올을 사용할 수 있다. 상기 산은 염산, 황산 및 질산으로 이루어진 군으로부터 선택된 하나 이상의 산, 또는 상기 산과 에탄올, 메탄올 및 부탄올로 이루어진 군으로부터 선택된 하나 이상의 알코올과의 혼합용매를 사용할 수 있다. 상기 염기는 수산화나트륨 및 수산화칼륨으로 이루어진 군으로부터 선택된 하나 이상의 염기, 또는 상기 염기와 에탄올, 메탄올, 부탄올로 이루어진 군으로부터 선택된 하나 이상의 알코올과의 혼합용매를 사용할 수 있다. 상기 효소 또는 상기 효소를 생산하는 미생물은 추출물에 함유된 녹차 사포닌의 당 결합을 분해하는 효소 또는 상기 당 결합을 분해하는 효소를 생산하는 미생물로서, 녹차 사포닌의 당 부분을 제거하여 21-O-안젤로일티아사포제놀 E3을 생성할 수 있는 것이다. 또한, 상기 효소는 글루코시다아제(glucosidase), 아라비노시다아제(arabinosidase), 람노시다아제(rhamnosidase), 자일로시다아제(xylosidase), 셀룰라아제(cellulase), 헤스페리디나아제(hesperidinase), 나린지나아제(naringinase), 글루쿠로니다아제(glucuronidase), 펙티나아제(pectinase), 갈락토시다아제(galactosidase) 및 아밀로글루코시다아제(amyloglucosidase)로 이루어진 군으로부터 선택된 하나 이상일 수 있다. 나아가, 상기 효소를 생산하는 미생물은 아스퍼질러스(aspergillus)속, 바실러스(bacillus)속, 페니실리움(penicillium)속, 리조푸스(rhizopus)속, 리조무코르(rhizomucor)속, 탈라로마이세스(talaromyces)속, 비피도박테리움(bifidobacterium)속, 모르티에렐라(mortierella)속, 크립토코커스(cryptococcus)속 및 마이크로박테리움(microbacterium)속으로 이루어진 군으로부터 선택된 하나 이상일 수 있다. The organic solvent may be at least one organic solvent selected from the group comprising ethanol, methanol, butanol, ether, ethyl acetate and chloroform or a mixture of water and 50% ethanol in one aspect. The acid may be one or more acids selected from the group consisting of hydrochloric acid, sulfuric acid and nitric acid, or a mixed solvent of the acid with one or more alcohols selected from the group consisting of ethanol, methanol and butanol. The base may be one or more bases selected from the group consisting of sodium hydroxide and potassium hydroxide, or a mixed solvent of the base and one or more alcohols selected from the group consisting of ethanol, methanol and butanol. The enzyme or microorganism producing the enzyme is an enzyme that breaks down the sugar bonds of the green tea saponin contained in the extract or an enzyme that breaks down the sugar bond, and removes the sugar portion of the green tea saponin to remove 21-O-angelo. Ilthia sapogenol E3 can be produced. In addition, the enzyme is glucosidase, arabinosidase, arachnosidase, rhamnosidase, xylosidase, cellulase, hesperidinase, naringininase It may be one or more selected from the group consisting of naringinase, glucuronidase, pectinase, galactosidase and amyloglucosidase. Furthermore, the microorganisms producing the enzyme are aspergillus genus, Bacillus genus, penicillium genus, rhizopus genus, rhizomucor genus, talaomyces (talaromyces), bifidobacterium (genus), mortierella (mortierella), genus Cryptococcus (cryptococcus) and microbacterium (microbacterium) may be one or more selected from the group consisting of.
상기와 같이, 산, 염기, 효소, 또는 상기 효소를 생산하는 미생물을 이용하여 가수분해 한 후, 반응액을 감압농축하여 용매를 제거하고, 잔사에 알코올을 가하여 1 내지 5회 교반시킨 후, 침전된 염들을 여과를 통하여 제거하고, 여과된 여액을 감압농축하여 조 생성물을 수득하고, 수득된 조 생성물을 실리카겔 컬럼 크로마토그래피(클로로포름:메탄올= 8:1~4:1)로 분리하여, 21-O-안젤로일티아사포제놀 E3를 수득할 수 있다. As described above, after hydrolysis using an acid, a base, an enzyme, or a microorganism producing the enzyme, the reaction solution is concentrated under reduced pressure to remove the solvent, and alcohol is added to the residue, followed by stirring 1 to 5 times, followed by precipitation. The obtained salts were removed through filtration, and the filtrate was concentrated under reduced pressure to give a crude product, and the obtained crude product was separated by silica gel column chromatography (chloroform: methanol = 8: 1-4: 1), and O-angeloylthiasapogenol E3 can be obtained.
일측면에서, 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3의 제조방법에 관한 특허출원 제10-2008-0088127호는 명세서 전체가 본 발명의 참조로서 포함된다. In one aspect, patent application No. 10-2008-0088127 relating to a method for preparing 21-O-angeloylthiasapogenol E3 derived from green tea saponin is incorporated by reference in its entirety.
본 명세서에 개시되는 조성물은 일측면에서 조성물 총 중량을 기준으로 0.001 내지 20 중량%의 화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3을 함유할 수 있고, 다른 일측면에서 0.01 내지 15 중량%, 0.01 내지 10 중량%, 또는 0.1 내지 5 중량% 함유할 수 있다. 일측면에서 본 명세서에 개시되는 조성물에 포함되는 화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3은 조성물 총 중량을 기준으로 0.001 중량% 이상, 0.01 중량% 이상, 0.1 중량% 이상, 또는 1.0 중량% 이상일 수 있으며, 다른 일측면에서 20 중량% 이하, 15 중량% 이하, 10중량% 이하, 또는 5 중량% 이하일 수 있다. 함유량이 0.001 중량% 미만인 경우에는 조성물의 발모 또는 육모 촉진 효과를 기대할 수 없고, 20 중량%를 초과하는 경우에는 안전성 또는 제형상 제조에 어려움이 있으나, 상기의 함유량에 특별히 한정되는 것은 아니다.The composition disclosed herein may contain, in one aspect, a thiasafozenol derivative or 21-O-angeloylthiasafogenol E3 represented by 0.001 to 20% by weight based on the total weight of the composition, and another one. 0.01 to 15% by weight, 0.01 to 10% by weight, or 0.1 to 5% by weight. In one aspect, the thiasapogenol derivative or 21-O-angeloylthiasapogenol E3 represented by Formula 1 included in the composition disclosed herein is at least 0.001% by weight, at least 0.01% by weight, and 0.1, based on the total weight of the composition. It may be at least weight percent, or at least 1.0 weight percent, and in another aspect, it may be 20 weight percent or less, 15 weight percent or less, 10 weight percent or less, or 5 weight percent or less. If the content is less than 0.001% by weight, the hair growth or hair growth promoting effect of the composition cannot be expected. If the content is more than 20% by weight, it is difficult to manufacture safety or formulation, but is not particularly limited to the above content.
본 명세서에 개시되는 조성물은 일측면에서 화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3을 포함하고, 모낭 모유두 세포를 증식시키는 효과를 갖는 조성물일 수 있다. 다른 일측면에서 본 명세서에 개시되는 조성물은 화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3을 포함하고, 케라틴 형성세포를 활성화시키는 조성물일 수 있다.The composition disclosed herein may be a composition comprising a thiasapogenol derivative or 21-O-angeloylthiasapogenol E3 represented by Formula 1 in one aspect and having an effect of proliferating follicular dermal papilla cells. In another aspect, the composition disclosed herein may be a composition comprising a thiasapogenol derivative represented by Formula 1 or 21-O-angeloylthiasapogenol E3 and activating keratinocytes.
본 명세서에 개시되는 조성물은 다른 일측면에서 화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3을 포함하고, PGE2, IL-6 또는 IL-8의 생성을 억제하는 효과를 갖는 조성물일 수 있다. The composition disclosed herein comprises a thiasapogenol derivative or 21-O-angeloylthiasapogenol E3 represented by Formula 1 in another aspect, and has an effect of inhibiting production of PGE2, IL-6 or IL-8. It may be a composition having.
본 발명의 발모 또는 육모 촉진용 조성물은 일측면에서, 약학 조성물, 화장료 조성물 또는 건강식품 조성물일 수 있다. In one aspect, the composition for promoting hair growth or hair growth may be a pharmaceutical composition, a cosmetic composition or a health food composition.
본 발명의 일 실시예에 따른 발모 또는 육모 촉진용 화장료 조성물에는 화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있다. 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다.In the cosmetic composition for promoting hair growth or hair growth according to an embodiment of the present invention, a functional additive and a component included in a general cosmetic composition, in addition to the thiasafogenol derivative represented by the general formula (1) or 21-O-angeloylthiasapogenol E3, are additionally added. May be included. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.
또한, 본 발명의 화장료 조성물에는 상기 기능성 첨가물과 더불어 필요에 따라 일반적인 화장료 조성물에 포함되는 성분을 배합할 수 있다. 이외에 포함되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.In addition, the cosmetic composition of the present invention may be blended with the above functional additives, if necessary, the components included in the general cosmetic composition. In addition to the other components included, oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, blood circulation And accelerators, cooling agents, limiting agents, purified water, and the like.
본 발명의 일 실시예에 따른 발모 또는 육모 촉진용 화장료 조성물은 제형이 특별히 한정되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. 예를 들어, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저로 이루어진 군으로부터 선택된 어느 하나 이상의 제형으로 제조될 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition for promoting hair growth or hair growth according to an embodiment of the present invention is not particularly limited, and may be appropriately selected as desired. For example, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing It may be prepared in any one or more formulations selected from the group consisting of foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal carriers, vegetable fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc. may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, and especially in the case of spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solvating or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the dosage form of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
화장료 조성물에 포함되는 유효성분인 화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3의 함량은 특별히 제한되지 않으나, 조성물 총 중량을 기준으로 0.001 내지 20 중량%일 수 있고, 다른 일측면에서 0.01 내지 15 중량%, 0.01 내지 10 중량%, 또는 0.1 내지 5 중량%일 수 있다. 상기 유효 성분이 상기 함량을 만족하는 경우 부작용 없이 우수한 효능을 나타낼 수 있다.The content of the thiasapogenol derivative or 21-O-angeloylthiasapogenol E3 represented by Formula 1, which is an active ingredient included in the cosmetic composition, is not particularly limited, but may be 0.001 to 20% by weight based on the total weight of the composition. In another aspect, it may be 0.01 to 15% by weight, 0.01 to 10% by weight, or 0.1 to 5% by weight. When the active ingredient satisfies the content, it may exhibit excellent efficacy without side effects.
본 발명의 일 실시예에 따른 발모 또는 육모 촉진용 약학 조성물은 화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3 이외에 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 약제학적 보조제 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 경구 투여제 또는 비경구 투여제 형태로 제형화할 수 있다.The pharmaceutical composition for promoting hair growth or hair growth according to an embodiment of the present invention is a preservative, stabilizer, wetting agent or emulsifier, osmotic pressure control in addition to the thiasapogenol derivative represented by the general formula (1) or 21-O-angeloylthiasapogenol E3 And pharmaceutical supplements such as salts and / or buffers and other therapeutically useful substances, and may be formulated in various oral or parenteral dosage forms in accordance with conventional methods.
상기 경구 투여제는 예를 들면, 정제, 환제, 경질 및 연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 분제, 산제, 세립제, 과립제, 펠렛제 등이 있으며, 이들 제형은 유효 성분 이외에 계면 활성제, 희석제(예: 락토즈, 덱스트로즈, 수크로즈, 만니톨, 솔비톨, 셀룰로오스 및 글리신), 활택제(예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및 폴리에틸렌 글리콜)를 함유할 수 있다. 정제는 또한 마그네슘 알루미늄 실리케이트, 전분페이스트, 젤라틴, 트라가칸스, 메틸셀룰로오스, 나트륨 카복시메틸셀룰로오스 및 폴리비닐피롤리딘과 같은 결합제를 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제, 흡수제, 착색제, 향미제, 및 감미제 등의 약제학적 첨가제를 함유할 수 있다. 상기 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.The oral dosage forms include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, powders, powders, fine granules, granules, pellets, and the like, and these formulations include surfactants in addition to the active ingredients. , Diluents (eg lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), glidants (eg silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols). . Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners. The tablets can be prepared by conventional mixing, granulating or coating methods.
또한, 상기 비경구 투여 형태로는 경피 투여형 제형일 수 있으며, 예를 들어 주사제, 점적제, 연고, 로션, 겔, 크림, 스프레이, 현탁제, 유제, 좌제(坐劑), 패취 등의 제형일 수 있으나, 이에 제한되는 것은 아니다. In addition, the parenteral dosage form may be a transdermal dosage form, for example, an injection, drop, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, or the like. It may be, but is not limited thereto.
본 발명의 일 실시예에 따른 상기 약학 조성물은 비경구, 직장, 국소, 경피, 피하 등으로 투여될 수 있다. 본 발명의 일 실시예에 따른 약학 조성물은 예를 들어 두피에 국소 투여될 수 있다.The pharmaceutical composition according to an embodiment of the present invention may be administered parenterally, rectally, topically, transdermally, subcutaneously, and the like. Pharmaceutical compositions according to one embodiment of the invention may be administered topically to the scalp, for example.
상기 유효 성분의 투여량 결정은 통상의 기술자의 수준 내에 있으며, 약물의 1일 투여 용량은 투여하고자 하는 대상의 미만 진행 정도, 발병 시기, 연령, 건강상태, 합병증 등의 다양한 요인에 따라 달라지지만, 성인을 기준으로 할 때 일측면에서 상기 조성물 1㎍/kg 내지 200mg/kg, 다른 일측면에서 50㎍/kg 내지 50mg/kg을 1일 1 내지 3회 분할하여 투여할 수 있으며, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.Determination of the dosage of the active ingredient is within the level of ordinary skill in the art, and the daily dosage of the drug depends on various factors such as less progression, onset, age, health condition, complications, etc. of the subject to be administered, On the basis of an adult, the composition may be administered by dividing 1 µg / kg to 200 mg / kg of the composition in one side and 50 µg / kg to 50 mg / kg in one side once or three times a day. It is not intended to limit the scope of the invention in any way.
또한, 본 발명의 일 실시예에 따른 발모 또는 육모 촉진용 조성물은 피부 외용제일 수 있으며, 상기 피부 외용제는 피부 외부에서 도포되는 어떠한 것이라도 포함될 수 있는 총칭으로서 다양한 제형의 화장품, 의약품이 여기에 포함될 수 있다.In addition, the composition for promoting hair growth or hair growth according to an embodiment of the present invention may be an external preparation for skin, wherein the external preparation for skin may include any of cosmetics and pharmaceuticals of various formulations as a generic term, which may include anything applied outside the skin. Can be.
본 발명의 일 실시예에 따른 건강식품 조성물에 있어서, 상기 조성물은 액상 또는 고체 상태의 제형일 수 있고, 정제, 캡슐제, 연질캡슐제, 환제, 과립제, 음료(드링크제), 다이어트바, 쵸콜렛, 카라멜 제형 또는 과자류 제형일 수 있으며, 그 제형에 특별히 한정되는 것은 아니다. 본 발명의 건강식품 조성물은 21-O-안젤로일티아사포제놀 E3인 유효 성분 외에도 필요에 따라 부형제, 당류, 향료, 색소, 유지류, 단백질 등을 적의 함유할 수 있다.In the health food composition according to an embodiment of the present invention, the composition may be a liquid or solid formulation, tablets, capsules, soft capsules, pills, granules, beverages (drinks), diet bar, chocolate, It may be a caramel formulation or a confectionary formulation, which is not particularly limited. In addition to the active ingredient 21-O-angeloylthiasapogenol E3, the health food composition of the present invention may optionally contain excipients, sugars, flavors, pigments, fats and oils, proteins, and the like.
건강식품 조성물에 포함되는 유효성분인 화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3의 함량은 특별히 제한되지 않으나, 조성물 총 중량을 기준으로 0.001 내지 20 중량%일 수 있고, 다른 일측면에서 0.01 내지 15 중량%, 0.01 내지 10 중량%, 또는 0.1 내지 5 중량%일 수 있다. 상기 유효 성분이 상기 함량을 만족하는 경우 부작용 없이 우수한 효능을 나타낼 수 있다.The content of the thiasapogenol derivative or 21-O-angeloylthiasapogenol E3 represented by Formula 1, which is an active ingredient included in the health food composition, is not particularly limited, but may be 0.001 to 20% by weight based on the total weight of the composition. In another aspect, it may be 0.01 to 15% by weight, 0.01 to 10% by weight, or 0.1 to 5% by weight. When the active ingredient satisfies the content, it may exhibit excellent efficacy without side effects.
이하의 실시예를 통하여 본 발명을 더욱 상세하게 설명한다. 단, 실시예는 본 발명을 예시하기 위한 것으로서 이들만으로 본 발명의 범위가 한정되는 것은 아니다.The present invention will be described in more detail with reference to the following examples. However, the examples are provided to illustrate the present invention, and the scope of the present invention is not limited only to these examples.
[제조예 1] 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3의 제조Preparation Example 1 Preparation of 21-O-angeloylthiasapogenol E3 Derived from Green Tea Saponin
녹차 종자 2kg에 헥산 6리터를 넣고, 상온에서 교반 추출하여 탈지시킨 다음, 탈지된 녹차 종자 1kg에 50% 에탄올 4리터를 넣고, 3회 환류 추출한 후, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통하여 잔사와 여액을 분리하고, 분리된 여액을 감압농축하여 얻은 엑기스를 물에 현탁한 후, 에테르 1리터로 5회 추출하여 색소를 제거하고, 수층을 1-부탄올 500ml로 3회 추출하였다. 이로부터 얻은 총 1-부탄올 층을 감압농축하여 1-부탄올 엑기스를 얻고, 이를 소량의 메탄올에 녹인 다음, 대량의 에틸아세테이트에 추가하여, 생성된 침전물을 건조함으로써 녹차 종자 추출물 300g을 수득하였다. 6 liters of hexane was added to 2 kg of green tea seeds, followed by stirring extraction at room temperature for degreasing. Then, 4 liters of 50% ethanol was added to 1 kg of degreased green tea seeds, followed by extraction under reflux three times, followed by immersion at 15 ° C. for 1 day. Thereafter, the residue and the filtrate were separated through filter cloth filtration and centrifugation. The extract obtained by concentrating the separated filtrate under reduced pressure was suspended in water, and then extracted five times with 1 liter of ether to remove the pigment, and the aqueous layer was 1-. Extracted three times with 500 ml of butanol. The total 1-butanol layer thus obtained was concentrated under reduced pressure to obtain 1-butanol extract, which was dissolved in a small amount of methanol, and then added to a large amount of ethyl acetate, and the resulting precipitate was dried to obtain 300 g of green tea seed extract.
상기에서 수득한 녹차 종자 추출물 10g에 20배(v/w)의 1N HCl-50% 메탄올 용액(v/v)을 가하고, 80℃ 수욕조에서 8시간 동안 가열 환류시켜, 녹차 종자 조 사포닌에 결합된 당들을 가수분해시켰다. 반응액을 감압농축하여 용매를 제거하고, 잔사에 에탄올(200ml)을 가해 교반시킨 후(3회), 침전된 염들을 여과를 통해 제거한 다음, 여과된 여액을 감압농축하여 조 생성물을 수득한 후, 수득된 조 생성물을 실리카겔 컬럼 크로마토그래피(클로로포름:메탄올= 7:1~3:1)로 분리하여 21-O-안젤로일티아사포제놀 E3 0.55을 수득하였다. Varian Gemini 2000 300MHz(Varian 사)를 이용하여, 상기 수득물이 21-O-안젤로일티아사포제놀 E3인지 확인하였으며, 결과는 본 명세서에서 참조하고 있는 특허출원 제10-2008-0088127호 발명의 상세한 설명의 실험예 1과 동일한 결과가 나왔다. 20 g (v / w) of 1N HCl-50% methanol solution (v / v) was added to 10 g of the green tea seed extract obtained above, and heated to reflux for 8 hours in an 80 ° C water bath to bind to green tea seed crude saponin. Sugars were hydrolyzed. The reaction solution was concentrated under reduced pressure to remove the solvent, and ethanol (200 ml) was added to the residue, followed by stirring (3 times). The precipitated salts were removed by filtration, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product thus obtained was separated by silica gel column chromatography (chloroform: methanol = 7: 1-3: 1) to give 0.55-21-O-angeloylthiasapogenol E3 0.55. Using Varian Gemini 2000 300 MHz (Varian Corporation), the obtained product was confirmed to be 21-O-angeloylthiasapogenol E3, and the results are detailed in the patent application No. 10-2008-0088127 to which the specification is referred. The same result as Experimental example 1 of description was shown.
[시험예 1] 모유두 세포에서 모발 성장인자 VEGF의 발현 평가Test Example 1 Expression of Hair Growth Factor VEGF in Hair Papillary Cells
21-O-안젤로일티아사포제놀 E3가 혈관형성에 필요한 성장인자로 모발의 성장기로 이동하는데 필요한 성장인자인 혈관 내피 성장 인자(Vascular endothelial growth factor; VEGF)를 발현시키는 정도를 평가하기 위해, 생체 외(in vitro) 시스템을 적용하여 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3 적용 후, 활성을 평가하였다.To evaluate the extent to which 21-O-angeloylthiasapogenol E3 expresses Vascular endothelial growth factor (VEGF), which is a growth factor required for migration to the hair growth phase as a growth factor necessary for angiogenesis, Activity was assessed after application of 21-O-angeloylthiasapogenol E3 derived from green tea saponin using an in vitro system.
상기 실험을 위해 47세 남성의 모유두 진피세포(Dermal Papilla Cell; DPC) (P.11) 4 X 105 cell을 12 웰 플레이트(well plate)에 씨딩(seeding)하고, 10% FBS (fetal bovine serum)를 함유하는 DMEM(Dulbecco's modified Eagle's medium) 배지에서 하룻밤 동안 배양하였다. 배양 후, 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3을 20ppm으로 처리하였다. 음성 대조군으로는 DMSO를 사용하였다. 24시간 후 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3이 처리된 혼합액을 수집(soup collect)하고 VEGF ELISA (Vascular endothelial growth factor Enzyme-Linked Immunosorbent Assay; R&D biosystems)를 사용하여 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3의 발현 정도를 확인하였다. 그리고 그 결과를 표 1에 나타내었다.For this experiment, 47-year-old male dermal papilla cells (DPC) (P.11) 4 X 10 5 cells were seeded in a 12 well plate and 10% FBS (fetal bovine serum). Cultured overnight in Dulbecco's modified Eagle's medium (DMEM) medium. After incubation, 21-O-angeloylthiasapogenol E3 derived from green tea saponin was treated with 20 ppm. DMSO was used as a negative control. After 24 hours, a 21-O-angeloylthiasapogenol E3-derived mixed solution derived from green tea saponin was collected and soaked with green tea saponin using VEGF ELISA (Vascular endothelial growth factor Enzyme-Linked Immunosorbent Assay; R & D biosystems). The expression level of 21-O-angeloylthiasapogenol E3 derived from was confirmed. The results are shown in Table 1.
표 1에서 볼 수 있듯이, 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3은 대조군과 비교하여 큰 효과의 차이가 나타남을 확인할 수 있으며, 모유두 세포에서 모발 성장인자 VEGF의 발현을 약 3배 이상 증가시켰다. 따라서, 본 발명에 따른 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3 은 우수한 모발 생성 촉진능을 가짐을 알 수 있다.As can be seen in Table 1, 21-O-angeloylthiasapogenol E3 derived from green tea saponin showed a large difference in effect compared to the control, and the expression of hair growth factor VEGF in dermal papilla cells was about 3 Increased more than twice. Therefore, it can be seen that 21-O-angeloylthiasapogenol E3 derived from green tea saponin according to the present invention has excellent hair production promoting ability.
[시험예 2] 모낭 모유두 세포 증식 효과 평가[Test Example 2] Evaluation of hair follicle papilla cell proliferation effect
모발을 구성하는 케라틴 단백질은 모근부 케라틴 형성세포(keratinocyte)에서 생성되며, 이 케라틴 형성세포는 모유두 세포로부터 분화된다. 따라서 본 발명에 따른 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3이 모유두 세포의 활성을 촉진한다면 그로부터 분화되는 케라틴 형성세포의 활성을 촉진시킬 수 있고, 나아가 모발 생성을 촉진할 수 있을 것이다.The keratin proteins that make up hair are produced in hair root keratinocytes, which are differentiated from dermal papilla cells. Therefore, if 21-O-angeloylthiasapogenol E3 derived from green tea saponin according to the present invention promotes the activity of dermal papilla cells, it can promote the activity of keratinocytes differentiated therefrom and further promote hair production. will be.
이에 본 실험에서는 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3의 모유두 세포 활성 촉진 효과를 하기와 같이 평가하였다. In this experiment, 21-O-angeloylthiasapogenol E3 derived from green tea saponin was evaluated as follows.
먼저, 본 발명에서는 사람 모유두 세포(Human dermal papilla cell, 서울대 권오상 교수) 세포주를 사용하였다. 상기 세포주는 10% 소혈청세럼(FBS)이 함유된 Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA)으로 5% CO2, 37℃가 유지되는 인큐베이터에서 24시간 동안 배양한 후, 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3을 1ppm, 10ppm 및 20ppm으로 각각 처리하였다. 음성 대조군으로는 DMSO를 사용하였다. 시험 물질을 처리한 후 24시간 경과 후에 WST-1 키트(Roche)를 사용하여 세포 증식능(%)을 측정하였다. 그 결과를 표2에 나타내었다.First, in the present invention, a human dermal papilla cell (Professor Oh Sang Kwon, Seoul National University) cell line was used. The cell line was incubated for 24 hours in an incubator maintained at 5% CO 2 , 37 ° C with Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) containing 10% bovine serum serum (FBS), 21-O-angeloylthiasapogenol E3 derived from green tea saponin was treated with 1 ppm, 10 ppm and 20 ppm, respectively. DMSO was used as a negative control. 24 hours after the test material was treated, the cell proliferation (%) was measured using the WST-1 kit (Roche). The results are shown in Table 2.
표 2에서 볼 수 있듯이, 본 발명에 따른 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3은 10ppm 및 20ppm 모두 두 세포의 증식을 유의미하게 증가시켰다. 특히, 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3을 20ppm 처리한 경우가 대조군 대비 약 1.5배 이상 높은 모유두 세포 증식 증가율을 나타내었다. 이는 본 발명에 따른 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3이 모유두 세포의 증식을 촉진시킬 수 있으며, 케라틴 형성세포의 활성 및 모발 생성도 보다 효과적으로 촉진할 수 있음을 의미한다.As can be seen from Table 2, 21-O-angeloylthiasapogenol E3 derived from green tea saponin according to the present invention significantly increased the proliferation of both cells at 10 ppm and 20 ppm. In particular, when 20 ppm of 21-O-angeloylthiasapogenol E3 derived from green tea saponin exhibited about 1.5 times higher growth rate of dermal papilla cells than the control group. This means that 21-O-angeloylthiasapogenol E3 derived from green tea saponin according to the present invention can promote the growth of dermal papilla cells and more effectively promote the activity and hair production of keratinocytes.
(20ppm)21-O-angeloylthiasapogenol E3
(20ppm)
(10ppm)21-O-angeloylthiasapogenol E3
(10ppm)
(1ppm)21-O-angeloylthiasapogenol E3
(1 ppm)
[시험예 3] 인체 모낭기관을 이용한 모발 성장 촉진 효과 평가Test Example 3 Evaluation of Hair Growth Promoting Effect Using Human Hair Follicle Organs
본 발명의 실제 인체 모낭기관에서의 모발 성장 촉진능을 확인한 실험을 실시하였다.Experiments were conducted to confirm the hair growth promoting ability in the actual human hair follicle organ of the present invention.
55세 남성의 후두부 두피조직으로부터 모낭 기관을 하나씩 분리하여 William's E 배지(L-글루타민(2mM), 인슐린(10㎍/ml), 히드로코르티손(40ng/ml), 항생제(1%), 항진균제(1%) 함유)에 배양하였다. 배양 후 3일째에 성장이 일어난 모낭을 선별하여 3mm로 자르고 선별한 모낭 조직에 대해, 약물을 처리하지 않은 경우를 대조군으로 하고, 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3 1ppm, 3ppm 및 5ppm을 각각 처리하였다. 그리고, 처리한지 8일 후 각각 길이 측정 및 사진촬영을 진행하였다. 그 결과를 표 3에 나타내었다.Hair follicles were isolated from the scalp and scalp tissue of a 55 year old male with William's E medium (L-glutamine (2 mM), insulin (10 µg / ml), hydrocortisone (40 ng / ml), antibiotics (1%), and antifungal agents (1). %) Containing). After 3 days of culture, the hair follicles grown on the screen were screened and cut into 3 mm, and the selected hair follicle tissues were treated as a control group without drug treatment, and 1 ppm of 21-O-angeloylthiasapogenol E3 derived from green tea saponin, 3 ppm and 5 ppm were treated respectively. After 8 days of treatment, length measurement and photographing were performed. The results are shown in Table 3.
그 결과, 표 3에서 볼 수 있듯이, 모낭 기관에서 모발의 길이 증가에 있어서 5ppm의 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3을 처리한 경우가 대조군보다 우수한 모발 성장 촉진 효과가 나타났다. 따라서 상기 표 3의 결과를 볼 때, 본 발명에 따른 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3은 모낭에서 모발의 길이 성장을 촉진하는 효과가 우수함을 알 수 있다. As a result, as shown in Table 3, 5-ppm green tea saponin-derived 21-O-angeloylthiasapogenol E3 in hair follicle organs showed a hair growth promoting effect better than the control group. . Therefore, when looking at the results of Table 3, it can be seen that 21-O-angeloylthiasapogenol E3 derived from green tea saponin according to the present invention has an excellent effect of promoting hair length growth in hair follicles.
(5ppm)21-O-angeloylthiasapogenol E3
(5ppm)
(3ppm)21-O-angeloylthiasapogenol E3
(3 ppm)
(1ppm)21-O-angeloylthiasapogenol E3
(1 ppm)
[시험예 4] PGE2, IL-6 및 IL-8 생성 억제 실험[Test Example 4] PGE2, IL-6 and IL-8 production inhibition experiment
사람의 섬유아세포를 6-웰 배양판에 1×105 세포의 농도로 접종하고, 24 시간 동안 37 ℃, 5 % CO2 인큐베이터에서 배양하였다. H2O2 500μM을 웰에 처리하여 24 시간 동안 자극을 준 후, 칼슘나무 추출물을 농도별로 처리하여 48 시간 동안 반응시켰다. 반응 완료 후 배양액을 수거하여 ELISA 분석을 수행하였다. 이때 항염 및 자극완화제로 많이 사용되는 물질인 알파-비사보롤(α-bisaborol)을 대조군으로 사용하였다. PGE2는 어세이 디자인(Assay Design)사의 키트, IL-6, IL-8은 엔도젠(Endogen)사의 키트를 사용하였으며, 각 회사의 매뉴얼에 명기된 방법에 따라 실험을 진행하였다. 억제 효과는 하기 수학식 1에 따라 계산하였으며, 측정 결과는 하기 표 4에 나타내었다.Human fibroblasts were seeded in 6-well culture plates at a concentration of 1 × 10 5 cells and incubated in 37 ° C., 5% CO 2 incubator for 24 hours. After treatment with 500 μM of H 2 O 2 for 24 hours to stimulate the well, calcium tree extract was treated by concentration to react for 48 hours. After completion of the reaction, the culture was collected and subjected to ELISA analysis. At this time, alpha-bisaborol (α-bisaborol), which is a material frequently used as an anti-inflammatory and irritant, was used as a control. PGE2 used Asay Design's kit, IL-6 and IL-8 used Endogen's kit, and the experiment was conducted according to the method specified in each company's manual. The inhibitory effect was calculated according to Equation 1 below, and the measurement results are shown in Table 4 below.
하기 표 4에 나타낸 바와 같이, 염증 매개 물질인 PGE2, IL-6, IL-8의 생성량이 본 발명의 녹차 사포닌으로부터 유래된 21-O-안젤로일티아사포제놀 E3 첨가에 의해 현저하게 줄어들어 높은 억제 효과를 보임을 확인할 수 있다. As shown in Table 4 below, the production of inflammatory mediators PGE2, IL-6, and IL-8 was significantly reduced by the addition of 21-O-angeloylthiasapogenol E3 derived from the green tea saponin of the present invention. You can see the effect.
[수학식 1][Equation 1]
억제 효과 = {1-(시험 시료-대조군)/(H2O2-대조군)} × 100Inhibitory effect = {1- (test sample-control) / (H 2 O 2 -control)} × 100
하기에 본 발명에 따른 조성물의 제형예를 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다. Examples of the formulation of the composition according to the present invention are described below, but are also applicable to various other formulations, which are intended to explain in detail only and not intended to limit the present invention.
[제형예 1] 샴푸 Formulation Example 1 Shampoo
하기 표 5에 기재된 조성에 따라 통상적인 방법으로 샴푸를 제조하였다.To prepare a shampoo in a conventional manner according to the composition shown in Table 5.
[제형예 2] 린스 Formulation Example 2 Rinse
하기 표 6에 기재된 조성에 따라 통상적인 방법으로 린스를 제조하였다.To prepare a rinse in a conventional manner according to the composition shown in Table 6.
[제형예 3] 연고Formulation Example 3 Ointment
하기 표 7에 기재된 조성에 따라 통상적인 방법으로 연고를 제조하였다.The ointment was prepared in a conventional manner according to the composition described in Table 7.
[제형예 4] 헤어토닉[Formulation Example 4] Hair Tonic
하기 표 8에 기재된 조성에 따라 통상적인 방법으로 연고를 제조하였다.The ointment was prepared in a conventional manner according to the composition described in Table 8.
[제형예 5] 헤어로션[Formulation Example 5] Hair Lotion
하기 표 9에 기재된 조성에 따라 통상적인 방법으로 연고를 제조하였다.Ointments were prepared in a conventional manner according to the compositions described in Table 9 below.
[제형예 6] 헤어비누Formulation Example 6 Hair Soap
하기 표 10에 기재된 조성에 따라 통상적인 방법으로 연고를 제조하였다.The ointment was prepared in a conventional manner according to the composition described in Table 10 below.
[제형예 7] 로션[Formulation Example 7] Lotion
하기 표 11에 기재된 조성에 따라 통상적인 방법으로 로션을 제조하였다.The lotion was prepared in a conventional manner according to the composition described in Table 11 below.
[제형예 8] 크림Formulation Example 8 Cream
하기 표 12에 기재된 조성에 따라 통상적인 방법으로 크림을 제조하였다.To prepare a cream in a conventional manner according to the composition shown in Table 12.
[제형예 9] 팩[Formulation Example 9] Pack
하기 표 13에 기재된 조성에 따라 통상적인 방법으로 팩을 제조하였다.To prepare a pack in a conventional manner according to the composition described in Table 13.
[제형예 10] 미용액형 제제Formulation Example 10 Cosmetic Liquid Formulation
하기 표 14에 기재된 조성에 따라 통상적인 방법으로 미용액형 제제를 제조하였다.To prepare a cosmetic liquid formulation in a conventional manner according to the composition shown in Table 14.
[제형예 11] 연질캅셀제Formulation Example 11 Soft Capsule
화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3 50mg, L-카르니틴 80~140mg, 대두유 180mg, 팜유 2mg, 식물성 경화유 8mg, 황납 4mg 및 레시틴 6mg을 혼합하고, 통상의 방법에 따라 1 캡슐당 400mg씩 충진하여 연질캅셀을 제조하였다.50 mg of thiasapogenol derivatives represented by the formula (1) or 21-O-angeloylthiasapogenol E3, 80-140 mg of L-carnitine, 180 mg of soybean oil, 2 mg of palm oil, 8 mg of vegetable hardened oil, 4 mg of lead wax, and 6 mg of lecithin are mixed. According to the method was filled 400mg per capsule to prepare a soft capsule.
[제형예 12] 정제Formulation Example 12 Tablets
화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3 50mg, 갈락토올리고당 200mg, 유당 60mg 및 맥아당 140mg을 혼합하고 유동층 건조기를 이용하여 과립한 후 당 에스테르(sugar ester)를 6mg을 첨가하여 타정기로 타정하여 정제를 제조하였다.50 mg of thiasapogenol derivatives represented by Formula 1 or 21-O-angeloylthiasapogenol E3, 200 mg of galactooligosaccharide, 60 mg of lactose and 140 mg of maltose were mixed and granulated using a fluidized bed dryer, and then a sugar ester was added. Tablets were prepared by adding 6 mg and tableting with a tablet press.
[제형예 13] 과립제Formulation Example 13 Granules
화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3 50mg, 무수결정 포도당 250mg 및 전분 550mg을 혼합하고, 유동층 과립기를 사용하여 과립으로 성형한 후 포에 충진하여 과립제를 제조하였다.50 mg of thiaspapogenol derivatives represented by the formula (1) or 21-O-angeloylthiasapogenol E3, 250 mg of anhydrous glucose, and 550 mg of starch were mixed, molded into granules using a fluidized bed granulator, and then filled into fabrics to prepare granules. It was.
[제형예 14] 드링크제Formulation Example 14 Drinks
화학식 1로 표현되는 티아사포제놀 유도체 또는 21-O-안젤로일티아사포제놀 E3 50mg, 포도당 10g, 구연산 0.6g, 및 액상 올리고당 25g을 혼합한 후 정제수 300ml를 가하여 각 병에 200ml씩 충진한다. 병에 충진한 후 130 ℃에서 4~5 초간 살균하여 드링크제 음료를 제조하였다.50 mg of a thiosapogenol derivative represented by Formula 1 or 21-O-angeloylthiasapogenol E3, 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharides were mixed, and 300 ml of purified water was added thereto, and 200 ml were filled in each bottle. After filling the bottle sterilized for 4-5 seconds at 130 ℃ to prepare a beverage drink.
Claims (10)
상기 21-O-안젤로일티아사포제놀 E3은 하기 화학식 2로 표현되는 것인 발모 또는 육모 촉진용 조성물.
[화학식 2]
The method of claim 1,
The 21-O-angeloylthiasapogenol E3 is a composition for promoting hair growth or hair growth is represented by the following formula (2).
[Formula 2]
상기 유효성분은 녹차 사포닌 추출물로부터 분리된 것인, 발모 또는 육모 촉진용 조성물.The method of claim 1,
The active ingredient is isolated from green tea saponin extract, hair growth or hair growth promoting composition.
상기 조성물은 상기 유효성분을 조성물 총 중량을 기준으로 0.001 내지 20중량% 함유하는 것인, 발모 또는 육모 촉진용 조성물.The method of claim 1,
The composition is to contain the active ingredient 0.001 to 20% by weight based on the total weight of the composition, hair growth or hair growth promoting composition.
상기 조성물은 모낭 모유두 세포를 증식시키는 효과를 갖는 것인, 발모 또는 육모 촉진용 조성물.The method of claim 1,
The composition is to have the effect of proliferating the hair follicle papilla cells, hair growth or hair growth promoting composition.
상기 조성물은 PGE2, IL-6 또는 IL-8 생성을 억제하는 효과를 갖는 것인, 발모 또는 육모 촉진용 조성물.The method of claim 1,
The composition is to have the effect of inhibiting the production of PGE2, IL-6 or IL-8, hair growth or hair growth promoting composition.
상기 조성물은 화장료 조성물인 것인, 발모 또는 육모 촉진용 조성물.The method according to any one of claims 1 and 3 to 7,
The composition is a cosmetic composition, hair growth or hair growth promoting composition.
상기 조성물은 약학 조성물인 것인, 발모 또는 육모 촉진용 조성물.The method according to any one of claims 1 and 3 to 7,
The composition is a pharmaceutical composition, hair growth or hair growth promoting composition.
상기 조성물은 식품 조성물인 것인, 발모 또는 육모 촉진용 조성물.The method according to any one of claims 1 and 3 to 7,
The composition is a food composition, hair growth or hair growth promoting composition.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130104230A KR102061716B1 (en) | 2013-08-30 | 2013-08-30 | Composition for promoting hair growth or restoration containing 21-o-angeloyltheasapogenol e3 |
JP2016538842A JP6386053B2 (en) | 2013-08-30 | 2014-08-21 | Hair growth or hair growth promoting composition containing 21-O-angeloyl theasapogenol E3 |
PCT/KR2014/007768 WO2015030422A1 (en) | 2013-08-30 | 2014-08-21 | Composition for accelerating hair restoration or hair growth, comprising 21-o-angeloyltheasapogenol e3 |
CN201480055367.1A CN105636593B (en) | 2013-08-30 | 2014-08-21 | Including the hair tonic of 21-O- angeloyl groups theasapogenols E3 or educating hair composition for promoting |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130104230A KR102061716B1 (en) | 2013-08-30 | 2013-08-30 | Composition for promoting hair growth or restoration containing 21-o-angeloyltheasapogenol e3 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150025984A KR20150025984A (en) | 2015-03-11 |
KR102061716B1 true KR102061716B1 (en) | 2020-01-02 |
Family
ID=52586904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130104230A KR102061716B1 (en) | 2013-08-30 | 2013-08-30 | Composition for promoting hair growth or restoration containing 21-o-angeloyltheasapogenol e3 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP6386053B2 (en) |
KR (1) | KR102061716B1 (en) |
CN (1) | CN105636593B (en) |
WO (1) | WO2015030422A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101957849B1 (en) * | 2015-03-31 | 2019-03-15 | (주)아모레퍼시픽 | Composition for promoting hair growth or restoration and anti-inflammatory composition |
KR102406000B1 (en) * | 2015-09-30 | 2022-06-08 | (주)아모레퍼시픽 | Composition for promoting hair growth and/or restoration containing soyasaponin |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5663160A (en) | 1992-09-17 | 1997-09-02 | Lvmh Recherche | Cosmetic or dermatological composition containing at least one saponin of the ginsenoside type, and its applications, especially for treating the hair |
US5723149A (en) | 1990-11-21 | 1998-03-03 | Lvmh Recherche | Use of medicago saponins for the preparation of cosmetic or pharmaceutical compositions, especially dermatological compositions, promoting renewal of the epidermis, stimulating hair regrowth or delaying hair loss |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1144082A (en) * | 1995-08-25 | 1997-03-05 | 蔡汉宏 | Tea seed hair-washing powder preparation technology |
US20020013294A1 (en) * | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20070129430A1 (en) * | 2003-10-07 | 2007-06-07 | Satomi Miyata | Agent for enhancing the production of collagen, their preparation and use |
CN101336970B (en) * | 2008-08-18 | 2012-02-15 | 盛立新 | Chinese herbal medicine for treating and preventing poliosis and alopecia |
KR101415995B1 (en) * | 2008-09-08 | 2014-07-08 | (주)아모레퍼시픽 | Method for preparing green tea saponin, 21-O-angeloyltheasapogenol E3 |
US20120277308A1 (en) * | 2010-07-16 | 2012-11-01 | Pacific Arrow Limited | compounds for treating cancer and other diseases |
KR101204034B1 (en) * | 2010-04-06 | 2012-11-27 | 박승덕 | Cosmetic composition for preventing hair loss and stimulating hair growth and Method for preparing the same |
KR101914157B1 (en) * | 2011-08-24 | 2018-12-31 | (주)아모레퍼시픽 | Cosmetic composition comprising camellia sinensis constituents |
-
2013
- 2013-08-30 KR KR1020130104230A patent/KR102061716B1/en active IP Right Grant
-
2014
- 2014-08-21 WO PCT/KR2014/007768 patent/WO2015030422A1/en active Application Filing
- 2014-08-21 JP JP2016538842A patent/JP6386053B2/en active Active
- 2014-08-21 CN CN201480055367.1A patent/CN105636593B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723149A (en) | 1990-11-21 | 1998-03-03 | Lvmh Recherche | Use of medicago saponins for the preparation of cosmetic or pharmaceutical compositions, especially dermatological compositions, promoting renewal of the epidermis, stimulating hair regrowth or delaying hair loss |
US5663160A (en) | 1992-09-17 | 1997-09-02 | Lvmh Recherche | Cosmetic or dermatological composition containing at least one saponin of the ginsenoside type, and its applications, especially for treating the hair |
Also Published As
Publication number | Publication date |
---|---|
CN105636593A (en) | 2016-06-01 |
KR20150025984A (en) | 2015-03-11 |
JP2016529287A (en) | 2016-09-23 |
WO2015030422A1 (en) | 2015-03-05 |
JP6386053B2 (en) | 2018-09-05 |
CN105636593B (en) | 2018-09-18 |
WO2015030422A9 (en) | 2016-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6697479B2 (en) | Composition for promoting hair growth or hair growth and for anti-inflammatory | |
US10967028B2 (en) | Composition for hair loss prevention or hair growth stimulation comprising Artemisia umbelliformis extract | |
KR101698922B1 (en) | Composition for promoting hair growth and restoration | |
KR101758144B1 (en) | Composition for anti-aging containing youngia denticulata extract | |
KR102429834B1 (en) | Composition comprising theasapogenol derivatives | |
JP6860558B2 (en) | Hair growth and / or hair growth promoting composition containing soyasaponin | |
KR102061716B1 (en) | Composition for promoting hair growth or restoration containing 21-o-angeloyltheasapogenol e3 | |
EP3205346B1 (en) | Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract | |
KR101810139B1 (en) | Composition for promoting hair growth and restoration | |
KR20200048141A (en) | Composition for for improving acne skin or inhibiting sebum secretion containing extract of ailanthi radicis cortex | |
KR20170136957A (en) | Composition for skin improvement comprising multiple extract | |
KR102564361B1 (en) | Composition for prevention of hair loss or promotion of hair growth comprising ginsenoside F5 | |
KR20210118272A (en) | A composition comprising kakkalide | |
JP2012236774A (en) | Fibroblast growth factor production promoter, vascular endothelial cell growth factor production promoter, and hair cosmetic | |
JP2017088539A (en) | Ceramide production promoter | |
KR20120119125A (en) | Skin whitening complex containing trihydroxyisoflavone and morus alba leaf extracts | |
KR20090070180A (en) | Composition comprising extracts of rubus coreanum miquel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |